GPCR signaling mediates tumor metastasis via PI3Kβ

Cancer Research

Volumn 76, Issue 10, 2016, Pages 2944-2953

  Khalil, Bassem D ^a   Hsueh, Christine ^a   Cao, Yanyan ^a   Saab, Widian F Abi ^a   Wang, Yarong ^a   Condeelis, John S ^a   Bresnick, Anne R ^a   Backer, Jonathan M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G BETA GAMMA PROTEIN; G PROTEIN COUPLED RECEPTOR; GELATIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHOTRANSFERASE; PROTEIN P110BETA; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; BREAST METASTASIS; CELL INVASION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PODOSOME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; APOPTOSIS; BREAST TUMOR; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG SCREENING; FEMALE; LUNG TUMOR; METABOLISM; PATHOLOGY; SCID MOUSE; SECONDARY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, SCID; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971516907     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1675     Document Type: Article

References (59)

1. Hanahan D, Coussens LM. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
2. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
3. Palacios-Arreola MI, Nava-Castro KE, Castro JI, Garcia-Zepeda E, Carrero JC, Morales-Montor J. The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. J Immunol Res 2014;2014: 849720.
4. Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 2012;287: 36593-608.
5. Marsigliante S, Vetrugno C, Muscella A. CCL20 induces migration and proliferation on breast epithelial cells. J Cell Physiol 2013;228:1873-83.
6. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
7. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, et al. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol 2011;38:1279-85.
8. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, et al. CCL18 from tumorassociated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011;19:541-55.
9. Yu M, Berk R, Kosir MA. CXCL7-mediated stimulation of lymphangiogenic factors VEGF-C, VEGF-D in human breast cancer cells. J Oncol 2010; 2010:939407.
10. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG. Stromal cell derived factor-1: Its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005;7:R402-10.
11. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
12. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
13. Cunningham HD, Shannon LA, Calloway PA, Fassold BC, Dunwiddie I, Vielhauer G, et al. Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes inmice. TranslOncol 2010; 3:354-61.
14. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 2006;103:9643-8.
15. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009;15:539-50.
16. Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011;30:449-63.
17. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009;69:6223-31.
18. Hernandez NA, Correa E, Avila EP, Vela TA, Perez VM. PAR1 is selectively over expressed in high grade breast cancer patients: A cohort study. J Transl Med 2009;7:47.
19. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002;296: 1636-9.
20. Kurosu H, Maehama T, Okada T, Yamamoto T, Hoshino S, Fukui Y, et al. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. J Biol Chem 1997;272:24252-6.
21. Murga C, Fukuhara S, Gutkind JS. A novel role for phosphatidylinositol 3- kinase beta in signaling from G protein-coupled receptors to Akt. J Biol Chem 2000;275:12069-73.
22. Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B. Gbetagammastimulates phosphoinositide 3-kinase-gammaby direct interaction with two domains of the catalytic p110 subunit. J Biol Chem 1998;273: 7024-9.
23. Dbouk HA, Vadas O, Shymanets A, Burke JE, Salamon RS, Khalil BD, et al. G protein-coupled receptor-mediated activation of p110beta by Gbetagamma is required for cellular transformation and invasiveness. Sci Signal 2012;5:89.
24. Vadas O, Dbouk HA, Shymanets A, Perisic O, Burke JE, Abi Saab WF, et al. Molecular determinants of PI3Kgamma-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc Natl Acad Sci U S A 2013;110:18862-7.
25. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3- kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7: 606-19.
26. Zardavas D, Phillips WA, Loi S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res 2014;16:201.
27. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011;19:715-27.
28. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 2008;1:3.
29. Carvalho S, Milanezi F, Costa JL, Amendoeira I, Schmitt F. PIKing the right isoform: The emergent role of the p110beta subunit in breast cancer. Virchows Arch 2010;456:235-43.
30. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, et al. Measurement of PIP3 levels reveals an unexpected role for p110beta in early adaptive responses to p110alpha-specific inhibitors in luminal breast cancer. Cancer Cell 2015;27:97-108.
31. Backer JM. The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol 2010;346:87-114.
32. Stanley ER.Murine bone marrow-derived macrophages. Methods Mol Biol 1997;75:301-4.
33. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colonystimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005;65:5278-83.
34. Starnes TW, Cortesio CL, Huttenlocher A. Imaging podosome dynamics and matrix degradation. Methods Mol Biol 2011;769:111-36.
35. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol- 3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007;5:195-201.
36. Patsialou A, Wang Y, Lin J, Whitney K, Goswami S, Kenny PA, et al. Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res 2012;14:R139.
37. Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park H, Coniglio SJ, et al. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res 2012;14:R23.
38. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
39. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009;4:e6562.
40. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
41. Paz H, Pathak N, Yang J. Invading one step at a time: The role of invadopodia in tumor metastasis. Oncogene 2014;33:4193-202.
42. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94.
43. Kirui JK, Xie Y, Wolff DW, Jiang H, Abel PW, Tu Y. Gbetagamma signaling promotes breast cancer cell migration and invasion. J Pharmacol Exp Ther 2010;333:393-403.
44. Tang X, Sun Z, Runne C, Madsen J, Domann F, Henry M, et al. A critical role of Gbetagamma in tumorigenesis and metastasis of breast cancer. J Biol Chem 2011;286:13244-54.
45. O'Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol 2014;27:126-35.
46. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
47. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73-86.
48. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004;64:7022-9.
49. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012;2012:948098.
50. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204.
51. Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, et al. The p110alpha andp110beta isoformsof PI3K play divergent roles inmammary gland development and tumorigenesis. Genes Dev 2012;26:1573-86.
52. Du J, Sun C, Hu Z, Yang Y, Zhu Y, Zheng D, et al. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS ONE 2010;5:e15940.
53. Brazzatti JA, Klingler-Hoffmann M, Haylock-Jacobs S, Harata-Lee Y, Niu M, Higgins MD, et al. Differential roles for the p101 and p84 regulatory subunits of PI3Kgamma in tumor growth and metastasis. Oncogene 2012;31:2350-61.
54. Roh-Johnson M, Bravo-Cordero JJ, Patsialou A, Sharma VP, Guo P, Liu H, et al. Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation. Oncogene 2014;33:4203-12.
55. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, et al. Essential roles of PI(3)Kp110beta in cell growth, metabolism and tumorigenesis. Nature 2008;454: 776-9.
56. Dou Z, Pan JA, Dbouk HA, Ballou LM, DeLeon JL, Fan Y, et al. Class IA PI3K p110beta subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation. Mol Cell 2013;50:29-42.
57. Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013;153:1050-63.
58. Salamon RS, Dbouk HA, Collado D, Lopiccolo J, Bresnick AR, Backer JM. Identification of the Rab5 binding site in p110beta: Assays for PI3Kbeta binding to Rab5. Methods Mol Biol 2015;1298:271-81.
59. Costa C, Martin-Conte EL, Hirsch E. Phosphoinositide 3-kinase p110gamma in immunity. IUBMB Life 2011;63:707-13.